Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 4.48 is 42% below its 5-year average of 7.73, near the low end of its 5-year range (4.48–14.65).
As of the fiscal period ended Tuesday, June 30, 2026. 8.90% below its 12-month average of 4.92.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.48.
CURRENT RATIO
4.48
CURRENT RATIO AVG TTM
4.92
CURRENT RATIO AVG 3Y
6.05
CURRENT RATIO AVG 5Y
7.73
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-8.90%
CURRENT VS 3Y AVG
-25.99%
CURRENT VS 5Y AVG
-42.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.34
median of 559 covered companies
CURRENT VS SECTOR MEDIAN
+34.17%
vs the sector median at left
Cytek Biosciences, Inc.
Market Cap
$772.27M
Current Ratio
4.48
TTM Avg
4.92
3Y Avg
6.05
5Y Avg
7.73
Market Cap
$772.90M
Current Ratio
13.37
TTM Avg
5.16
3Y Avg
5.50
5Y Avg
4.90
Market Cap
$762.06M
Current Ratio
9.39
TTM Avg
11.79
3Y Avg
11.79
5Y Avg
11.79
Market Cap
$759.16M
Current Ratio
18.86
TTM Avg
23.23
3Y Avg
26.78
5Y Avg
32.61
Market Cap
$788.35M
Current Ratio
2.07
TTM Avg
1.18
3Y Avg
1.89
5Y Avg
3.24
Market Cap
$748.37M
Current Ratio
16.09
TTM Avg
8.04
3Y Avg
7.87
5Y Avg
9.13
Market Cap
$808.29M
Current Ratio
4.26
TTM Avg
4.46
3Y Avg
3.96
5Y Avg
4.08
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $772.27M | 4.48 | 4.92 | 6.05 | 7.73 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $772.90M | 13.37 | 5.16 | 5.50 | 4.90 |
| Geron Corporation (GERN)vs › | $773.03M | 6.92 | 5.11 | 3.93 | 4.38 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $762.06M | 9.39 | 11.79 | 11.79 | 11.79 |
| Design Therapeutics, Inc. (DSGN)vs › | $759.16M | 18.86 | 23.23 | 26.78 | 32.61 |
| Mesa Laboratories, Inc. (MLAB)vs › | $788.35M | 2.07 | 1.18 | 1.89 | 3.24 |
| AdaptHealth Corp. (AHCO)vs › | $796.60M | 1.12 | 1.18 | 1.21 | 1.17 |
| Candel Therapeutics, Inc. (CADL)vs › | $748.37M | 16.09 | 8.04 | 7.87 | 9.13 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $808.29M | 4.26 | 4.46 | 3.96 | 4.08 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $731.98M | 19.31 | 14.05 | 7.67 | 5.91 |
Current Ratio
4.48
Quick Ratio
3.86
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 4.48 |
| 2026-03-31 | 4.69 |
| 2025-12-31 | 5.04 |
| 2025-09-30 | 5.17 |
| 2025-06-30 | 5.22 |
| 2025-03-31 | 5.62 |
| 2024-12-31 | 5.86 |
| 2024-09-30 | 6.21 |
| 2024-06-30 | 7.33 |
| 2024-03-31 | 6.99 |
| 2023-12-31 | 6.97 |
| 2023-09-30 | 7.20 |
| 2023-06-30 | 7.93 |
| 2023-03-31 | 7.53 |
| 2022-12-31 | 9.26 |
| 2022-09-30 | 10.70 |
| 2022-06-30 | 10.47 |
| 2022-03-31 | 10.26 |
| 2021-12-31 | 13.01 |
| 2021-09-30 | 14.65 |
| 2021-06-30 | 7.70 |
| 2021-03-31 | 7.66 |
| 2020-12-31 | 7.86 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
